Clinical Trial Update: Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A [NA]

View source ↗

Summary

This clinical trial update investigates the efficacy and safety of Advate (recombinant factor VIII) for standard prophylaxis in severe or moderately severe Hemo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Hemophilia A | NA | Status: UNKNOWN